Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/15138
Title
Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis
Author(s)
Sepulveda-Crespo, Daniel ISCIII | Yélamos, María Belén | Díez, Cristina | Gómez, Julián | Hontañón, Víctor | Torresano-Felipe, Francisco | Berenguer, Juan | González-García, Juan | Ibañez-Samaniego, Luis | Llop, Elva | Olveira, Antonio | Martínez, Javier | Resino, Salvador ISCIII | Martinez, Isidoro ISCIII
Date issued
2022-06
Citation
Biomed Pharmacother. 2022 Jun;150:113024.
Language
Inglés
Document type
journal article
Abstract
Objectives: The current study aimed to assess the impact of HIV on the production of anti-HCV antibodies in HCV-infected individuals with advanced HCV-related cirrhosis before and 36 weeks after the sustained virological response (SVR) induced by direct-acting antivirals (DAAs) therapy. Methods: Prospective study on 62 patients (50 HIV/HCV-coinfected and 12 HCV-monoinfected). Plasma anti-E2 and HCV-nAbs were determined respectively by ELISA and microneutralization assays. Results: At baseline, the HCV-group had higher anti-E2 levels against Gt1a (p = 0.012), Gt1b (p = 0.023), and Gt4a (p = 0.005) than the HIV/HCV-group. After SVR, anti-E2 titers against Gt1a (p < 0.001), Gt1b (p = 0.001), and Gt4a (p = 0.042) were also higher in the HCV-group than HIV/HCV-group. At 36 weeks post-SVR, plasma anti-E2 titers decreased between 1.3 and 1.9-fold in the HIV/HCV-group (p < 0.001) and between 1.5 and 1.8-fold in the HCV-group (p ≤ 0.001). At baseline, the HCV-group had higher titers of HCV-nAbs against Gt1a (p = 0.022), Gt1b (p = 0.002), Gt2a (p < 0.001), and Gt4a (p < 0.001) than the HIV/HCV-group. After SVR, HCV-nAbs titers against Gt1a (p = 0.014), Gt1b (p < 0.001), Gt2a (p = 0.002), and Gt4a (p = 0.004) were also higher in the HCV-group. At 36 weeks post-SVR, HCV-nAbs decreased between 2.6 and 4.1-fold in the HIV/HCV-group (p < 0.001) and between 1.9 and 4.0-fold in the HCV-group (p ≤ 0.001). Conclusions: HIV/HCV-coinfected patients produced lower levels of broad-spectrum anti-HCV antibodies than HCV-monoinfected patients.
Subject
Hepatitis C | HIV | HIV/HCV coinfection | Broad-spectrum neutralizing antibodies | Direct-acting antivirals | HCV clearance
MESH
Coinfection | HIV Infections | Hepatitis C, Chronic | Antibodies, Neutralizing | Antiviral Agents | Broadly Neutralizing Antibodies | Hepacivirus | Hepatitis C Antibodies | Humans | Liver Cirrhosis | Prospective Studies
Online version
DOI
Collections